Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind active-controlled trial of Lu AF35700 in treatment-resistant schizophrenia
2014-003569-12Phase 3Completed
- Sponsor
- Lundbeck
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lu af35700 in schizophrenia (4 arms), sponsored by Lundbeck. Primary endpoint: Symptoms of schizophrenia. Started Mar 2016; status: completed.
02
Drugs
lu af35700
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2014-003569-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003569-12.